FR2649322A1 - Complexes biodisponibles d'acide (alpha)-linolenique, extraits de plantes en contenant et compositions pharmaceutiques les incorporant - Google Patents
Complexes biodisponibles d'acide (alpha)-linolenique, extraits de plantes en contenant et compositions pharmaceutiques les incorporant Download PDFInfo
- Publication number
- FR2649322A1 FR2649322A1 FR8908987A FR8908987A FR2649322A1 FR 2649322 A1 FR2649322 A1 FR 2649322A1 FR 8908987 A FR8908987 A FR 8908987A FR 8908987 A FR8908987 A FR 8908987A FR 2649322 A1 FR2649322 A1 FR 2649322A1
- Authority
- FR
- France
- Prior art keywords
- complex
- linolenic acid
- phospholipid
- pharmaceutical composition
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 title claims abstract description 24
- 229960004488 linolenic acid Drugs 0.000 title claims abstract description 19
- 235000020661 alpha-linolenic acid Nutrition 0.000 title claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 20
- 239000000419 plant extract Substances 0.000 title description 3
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 9
- 125000002252 acyl group Chemical group 0.000 claims abstract description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 6
- 125000001183 hydrocarbyl group Chemical class 0.000 claims abstract description 5
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical group C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims abstract description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 3
- 239000000194 fatty acid Substances 0.000 claims abstract description 3
- 229930195729 fatty acid Natural products 0.000 claims abstract description 3
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 3
- 229930182830 galactose Natural products 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
- CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical group OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims abstract description 3
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 3
- 241000196324 Embryophyta Species 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 10
- 230000000202 analgesic effect Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 6
- 239000003981 vehicle Substances 0.000 claims description 6
- 230000001754 anti-pyretic effect Effects 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000011200 topical administration Methods 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 241001128145 Resedaceae Species 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- 239000000287 crude extract Substances 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 230000004060 metabolic process Effects 0.000 claims description 4
- 239000002798 polar solvent Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 235000006463 Brassica alba Nutrition 0.000 claims description 3
- 244000140786 Brassica hirta Species 0.000 claims description 3
- 244000180419 Brassica nigra Species 0.000 claims description 3
- 235000011291 Brassica nigra Nutrition 0.000 claims description 3
- 241000254191 Harpagophytum procumbens Species 0.000 claims description 3
- 241000208202 Linaceae Species 0.000 claims description 3
- 241000371126 Linum campanulatum Species 0.000 claims description 3
- 241000083552 Oligomeris Species 0.000 claims description 3
- 241000207960 Pedaliaceae Species 0.000 claims description 3
- 241000703262 Phyteuma Species 0.000 claims description 3
- 235000011483 Ribes Nutrition 0.000 claims description 3
- 241000220483 Ribes Species 0.000 claims description 3
- 235000004789 Rosa xanthina Nutrition 0.000 claims description 3
- 241000220222 Rosaceae Species 0.000 claims description 3
- 241000220151 Saxifragaceae Species 0.000 claims description 3
- 229940114079 arachidonic acid Drugs 0.000 claims description 3
- 235000021342 arachidonic acid Nutrition 0.000 claims description 3
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 3
- 239000012454 non-polar solvent Substances 0.000 claims description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 150000003180 prostaglandins Chemical class 0.000 claims description 3
- 210000000614 rib Anatomy 0.000 claims description 3
- 244000308505 Filipendula ulmaria Species 0.000 claims description 2
- 235000016622 Filipendula ulmaria Nutrition 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 241001136639 Reseda alba Species 0.000 claims description 2
- 241001016410 Reseda glauca Species 0.000 claims description 2
- 241001167724 Reseda lutea Species 0.000 claims description 2
- 241001016380 Reseda luteola Species 0.000 claims description 2
- 241001016364 Reseda suffruticosa Species 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 244000024671 Brassica kaber Species 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 1
- DTOSIQBPPRVQHS-UHFFFAOYSA-N α-Linolenic acid Chemical compound CCC=CCC=CCC=CCCCCCCCC(O)=O DTOSIQBPPRVQHS-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract description 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000003563 glycoside group Chemical group 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 19
- 238000012360 testing method Methods 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229960005489 paracetamol Drugs 0.000 description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indomethacin Natural products CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- JJBCTCGUOQYZHK-UHFFFAOYSA-N 2-acetyloxybenzoate;(5-amino-1-carboxypentyl)azanium Chemical compound OC(=O)C(N)CCCC[NH3+].CC(=O)OC1=CC=CC=C1C([O-])=O JJBCTCGUOQYZHK-UHFFFAOYSA-N 0.000 description 4
- 206010020843 Hyperthermia Diseases 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000036031 hyperthermia Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- WECIKJKLCDCIMY-UHFFFAOYSA-N 2-chloro-n-(2-cyanoethyl)acetamide Chemical compound ClCC(=O)NCCC#N WECIKJKLCDCIMY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000001890 Ribes hudsonianum Species 0.000 description 1
- 235000016954 Ribes hudsonianum Nutrition 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000111146 Sonchus arvensis Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- INAPMGSXUVUWAF-GCVPSNMTSA-N [(2r,3s,5r,6r)-2,3,4,5,6-pentahydroxycyclohexyl] dihydrogen phosphate Chemical compound OC1[C@H](O)[C@@H](O)C(OP(O)(O)=O)[C@H](O)[C@@H]1O INAPMGSXUVUWAF-GCVPSNMTSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940100656 nasal solution Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003907 phosphatidylinositol monophosphates Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8908987A FR2649322A1 (fr) | 1989-07-04 | 1989-07-04 | Complexes biodisponibles d'acide (alpha)-linolenique, extraits de plantes en contenant et compositions pharmaceutiques les incorporant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8908987A FR2649322A1 (fr) | 1989-07-04 | 1989-07-04 | Complexes biodisponibles d'acide (alpha)-linolenique, extraits de plantes en contenant et compositions pharmaceutiques les incorporant |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2649322A1 true FR2649322A1 (fr) | 1991-01-11 |
| FR2649322B1 FR2649322B1 (enrdf_load_stackoverflow) | 1994-08-19 |
Family
ID=9383463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR8908987A Granted FR2649322A1 (fr) | 1989-07-04 | 1989-07-04 | Complexes biodisponibles d'acide (alpha)-linolenique, extraits de plantes en contenant et compositions pharmaceutiques les incorporant |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2649322A1 (enrdf_load_stackoverflow) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0502765A1 (fr) * | 1991-03-05 | 1992-09-09 | Institut De Recherche Biologique S.A. | Nouvelles compositions diététiques à base de lipides complexes phosphorés et leur utilisation dans les troubles du sommeil |
| EP0516034A1 (en) * | 1991-05-28 | 1992-12-02 | FIDIA S.p.A. | Pharmaceutical compositions with immunosuppresive properties |
| EP0582239A1 (de) * | 1992-08-04 | 1994-02-09 | Rhone-Poulenc Rorer Gmbh | Pharmazeutische und/oder kosmetische Zubereitung sowie die Verwendung einer derartigen Zubereitung |
| WO2006117404A3 (de) * | 2005-05-04 | 2007-06-28 | Coty Prestige Lancaster Group | Topische verwendung von radikalfangenden substanzen zur antipyretischen behandlung |
| WO2009026944A1 (en) * | 2007-08-27 | 2009-03-05 | Dsm Ip Assets B.V. | Tryptase inhibiting mustard extract |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0148303A1 (de) * | 1984-01-11 | 1985-07-17 | von Mletzko, Armin, Dr. | Diätetikum |
-
1989
- 1989-07-04 FR FR8908987A patent/FR2649322A1/fr active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0148303A1 (de) * | 1984-01-11 | 1985-07-17 | von Mletzko, Armin, Dr. | Diätetikum |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0502765A1 (fr) * | 1991-03-05 | 1992-09-09 | Institut De Recherche Biologique S.A. | Nouvelles compositions diététiques à base de lipides complexes phosphorés et leur utilisation dans les troubles du sommeil |
| FR2673512A1 (fr) * | 1991-03-05 | 1992-09-11 | Inst Rech Biolog Sa | Nouvelles compositions dietetiques a base de lipides complexes phosphores et leur utilisation dans les troubles du sommeil. |
| EP0516034A1 (en) * | 1991-05-28 | 1992-12-02 | FIDIA S.p.A. | Pharmaceutical compositions with immunosuppresive properties |
| EP0582239A1 (de) * | 1992-08-04 | 1994-02-09 | Rhone-Poulenc Rorer Gmbh | Pharmazeutische und/oder kosmetische Zubereitung sowie die Verwendung einer derartigen Zubereitung |
| WO1994003156A1 (de) * | 1992-08-04 | 1994-02-17 | Rhône-Poulenc Rorer GmbH | Pharmazeutische und/oder kosmetische zubereitung sowie die verwendung einer derartigen zubereitung |
| WO2006117404A3 (de) * | 2005-05-04 | 2007-06-28 | Coty Prestige Lancaster Group | Topische verwendung von radikalfangenden substanzen zur antipyretischen behandlung |
| WO2009026944A1 (en) * | 2007-08-27 | 2009-03-05 | Dsm Ip Assets B.V. | Tryptase inhibiting mustard extract |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2649322B1 (enrdf_load_stackoverflow) | 1994-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3889481B2 (ja) | 医薬組成物 | |
| CA1302266C (en) | Formulations containing unsaturated fatty acids for the synthesis of prostaglandins and hydroxy-fatty acids in biological systems | |
| JPH07500566A (ja) | ネルボン酸及び長鎖脂肪酸の脱髄疾患の治療のための使用 | |
| JPH10245337A (ja) | 薬学的組成物 | |
| FR2523443A1 (fr) | Nouvelles formulations pharmaceutiques contenant le coenzyme q10 adaptees pour l'administration topique | |
| FR2914188A1 (fr) | Nouvelle composition a base d'oxime de cholest-4-en-3-one | |
| JPS6377817A (ja) | 治療用組成物 | |
| US2823164A (en) | Method of preparing 3, 5, 3' l-tri-iodothyronine and pharmaceutical compositions thereof | |
| FR2581310A1 (fr) | Composition therapeutique comportant de l'acide a-linolenique et un compose susceptible de favoriser le passage de l'acide au travers de la membrane cellulaire et extrait de plantes comprenant l'acide et le compose | |
| CH630528A5 (fr) | Nouvel extrait vegetal a partir de chrysanthellum. | |
| FR2630916A1 (fr) | Compositions pharmaceutiques de polypeptides adaptees a la resorption gastro-intestinale | |
| US5284873A (en) | Pharmaceutical compositions derived from the acid fraction of lipid extracts of sabal serrulata, with adrenergic antagonist activity and method of preparing said composition | |
| JPS58159414A (ja) | 薬剤組成物 | |
| JP5671524B2 (ja) | 心血管障害の治療用医薬組成物及びその使用 | |
| FR2649322A1 (fr) | Complexes biodisponibles d'acide (alpha)-linolenique, extraits de plantes en contenant et compositions pharmaceutiques les incorporant | |
| FR2678836A1 (fr) | Formulations pour voie orale d'ubidecarenone sous la forme de solutions aqueuses. | |
| JP2647882B2 (ja) | 鮫組織から単離した有効成分 | |
| JPS61271220A (ja) | カスタノスペルミン抗糖尿病剤 | |
| EP0317453A1 (fr) | Compositions médicamenteuses à base de flavonoides et de saponines extraits de chrysanthellum, leur procédé de préparation et applications thérapeutiques | |
| JPH0567123B2 (enrdf_load_stackoverflow) | ||
| JPH0319207B2 (enrdf_load_stackoverflow) | ||
| BE882889A (fr) | Sel de lysine de l'acide meta-benzoyl-hydratropique, son procede de preparation et compositions pharmaceutiques en contenant | |
| FR2459658A1 (fr) | Procede de preparation d'une composition pharmaceutique a base de methoxsalen administrable par voie orale | |
| JPS63188623A (ja) | 吸収改善ユビデカレノン製剤 | |
| BE1003959A5 (fr) | Agent therapeutique pour le traitement de troubles associes a l'ischemie cerebrale. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property | ||
| ST | Notification of lapse |
Effective date: 20080331 |